Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Dassault Systèmes SE
  6. News
  7. Summary
    DSY   FR0000130650

DASSAULT SYSTÈMES SE

(DSY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dassault Systemes : Medidata Acquires Digital Biomarker Business of MC10, Enhancing Remote Biometric Data Capture Capabilities in Hybrid and Virtual Clinical Trials

10/28/2020 | 08:00am EDT

Medidata, a Dassault Systemes company, the global leader in creating end-to-end solutions to support the entire clinical development process, acquired the digital biomarker business of MC10.

MC10's offerings will bring novel clinical analytics and biosensor capabilities to Medidata's existing Patient Cloud solutions in ePRO (patient-reported outcomes), eCOA (clinical outcome assessments), and biomarker discovery. This will enhance Medidata's capabilities of integrating data from wearable sensors - including clinical grade metrics - to help customers successfully virtualize clinical trials.

Remote, patient-centered technologies have become an essential part of clinical research, especially in the age of COVID-19; the physical restrictions placed on patients and clinical sites caused by the pandemic can interfere with launching a clinical study and carrying it to completion. Wearable sensors are used in about 15 percent of studies, and the use of sensors is expected to grow to approximately 70 percent by 2025.*

Medidata leads the industry in building and integrating new technologies to revolutionize clinical research in pursuit of patient-centric therapy development. MC10's focus on clinical grade data capture and novel digital biomarker development represent an important next chapter - advancing the understanding of disease progression and treatment effect in the home.

'Medidata is excited to add the pioneering work at MC10 to our ongoing efforts in building a new platform for ingestion and analytics across a wide array of mobile sensors,' said Anthony Costello, senior vice president, Mobile Health, Medidata. 'Incorporating remote biometric data capture and analysis that includes the MC10 nPoint Biostamp, alongside other leading mobile devices, will further strengthen the Medidata platform and help propel the digital transformation of life sciences.'

An integrated Medidata offering will provide research companies and device developers new and innovative ways to collect, normalize and analyze data in pursuit of new therapy development. This enhanced capability will also create a closer connection between patients and the ecosystem of trailblazing researchers, practitioners, and life science companies committed to deepening a shared understanding of disease, transformational therapies, and novel endpoints.

'Medidata is an exceptional fit for MC10. Our combined expertise will help customers and partners take a more data-driven approach to bringing targeted therapies to patients,' said Ben Schlatka, co-founder and CEO, MC10. 'We are looking forward to moving ahead together, accelerating the development and deployment of new innovative offerings for our customers and ultimately transforming therapy development to improve the lives of patients.'

Medidata is a wholly owned subsidiary of Dassault Systemes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

*Intel, 'AI and Wearables Bring New Data and Analytics to Clinical Trials,' 2017.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systemes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.

Medidata, Rave, and myMedidata are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systemes.

About Dassault Systemes

Dassault Systemes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating 'virtual experience twins' of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production.

Dassault Systemes' 20,000 employees are bringing value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit http://www.3ds.com

About MC10

MC10 is a privately held company focused on improving human health through digital solutions. The company combines conformal BioStamp sensors with clinical analytics to unlock novel insights from physiological data collected from the home or in clinical settings. Our flagship product, BioStamp nPoint, is intended for the clinical research community. MC10 is headquartered in Lexington, MA.

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
DASSAULT SYSTÈMES SE 1.12% 194.45 Real-time Quote.15.74%
All news about DASSAULT SYSTÈMES SE
06/10DASSAULT SYSTEMES  : Medidata Launches myMedidata Registries to Transform Awaren..
AQ
06/06Software maker Altium rejects $3.9 billion takeover bid from Autodesk
RE
06/04DASSAULT SYSTEMES  : 2021 voting results
PU
06/04Alstom Chooses Accenture and Dassault Systemes to Develop New Cloud Platform ..
AQ
06/03Atos Completes Acquisition Of Processia
MT
05/31DASSAULT SYSTÈMES SE  : Monthly statement on outstanding equity shares and votin..
CO
05/28DASSAULT SYSTÈMES SE : Ex-dividend day for final dividend
FA
05/27DASSAULT SYSTÈMES : Disclosure of trading in own shares
GL
05/27DASSAULT SYSTEMES  : Approves 5-For-1 Stock Split
MT
05/27DASSAULT SYSTEMES  : Five-for-one stock split on july 7, 2021
GL
More news
Financials
Sales 2021 4 786 M 5 803 M 5 803 M
Net income 2021 709 M 860 M 860 M
Net Debt 2021 1 016 M 1 231 M 1 231 M
P/E ratio 2021 70,8x
Yield 2021 0,41%
Capitalization 50 328 M 61 026 M 61 023 M
EV / Sales 2021 10,7x
EV / Sales 2022 9,64x
Nbr of Employees 21 451
Free-Float 49,8%
Chart DASSAULT SYSTÈMES SE
Duration : Period :
Dassault Systèmes SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DASSAULT SYSTÈMES SE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 194,64 €
Last Close Price 192,30 €
Spread / Highest target 19,6%
Spread / Average Target 1,21%
Spread / Lowest Target -23,0%
EPS Revisions
Managers and Directors
NameTitle
Bernard Charlès Vice Chairman & Chief Executive Officer
Dominique Florack President
Pascal Daloz Chief Operating & Financial Officer
Charles Edelstenne Chairman
Laurence Barthès Executive VP, Chief People & Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
DASSAULT SYSTÈMES SE15.74%60 878
MICROSOFT CORPORATION15.95%1 942 318
SEA LIMITED39.51%145 630
ZOOM VIDEO COMMUNICATIONS, INC.8.62%107 958
ATLASSIAN CORPORATION PLC4.37%61 311
ROBLOX CORPORATION0.00%52 892